Dimensional Fund Advisors
VIRX

Dimensional Fund Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Dimensional Fund Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-52,888
Closed -$55K – 3466
2023
Q3 		$55K Hold
52,888
– – ﹤0.01% 3372
2023
Q2 		$74.6K Sell
52,888
-71,543
-57% -$102K ﹤0.01% 3365
2023
Q1 		$198K Sell
124,431
-55,190
-31% -$100K ﹤0.01% 3204
2022
Q4 		$263 Buy
179,621
+33,290
+23% +$97.2K ﹤0.01% 3176
2022
Q3 		$625K Buy
+146,331
New +$620K ﹤0.01% 2994

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors's VIRX Position: Q4 2023 in Review

Dimensional Fund Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2023, closing a stake of 52,888 shares — an estimated $55K sold.

Dimensional Fund Advisors first reported a position in VIRX in Q3 2022 and held it in 5 quarters. The position peaked at $625K in Q3 2022. 42 funds tracked by Wall St. Rank hold VIRX as of Q4 2023.

  • Dimensional Fund Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Dimensional Fund Advisors sold 52,888 Viracta Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $55K.
  • Dimensional Fund Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
  • Dimensional Fund Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $625K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Dimensional Fund Advisors's 13F filing for Q4 2023, filed 7 Feb 2024.